Lecture series on the doctoring of madness and the creation of psychopharmacology, held at the Unversity Hospital of Psychiatry, Zurich 2008.

1. Felix Hasler Klinische Forschung The Creation of Psychopharmacology III David Healy, Harvard University Press, 2002 HRC Zürich

2. Von den Neuroleptika zu den Antipsychotica Pipamperone (Dipiperon ® ) Risperidon (Risperdal ® ) 1993

3. Von den Neuroleptika zu den Antipsychotica Lundbeck: Sertindol (Serdolect ® 1996) Komplikation: Verlängerung des QT-Intervalls

4. Exkurs Herzphysiologie

5. Erstes EKG (1903)

6. Sertindol (Serdolect ® 1996) Komplikation: Verlängerung des QT-Intervalls

7. Rezeptorbindungs-Profil Sertindol (Seroquel)

8. ECDEU: Empirische Wissenschaft Max Fink Nathan Kline Leo Hollister

9. Positive symptoms Negative symptoms Cognitive symptoms Behavioral symptoms „ EGO- DISORDER“ Positive and negative schizophrenia

10. Externe / Interne Stimuli Externe / Interne Stimuli Filter intakt Filter „gestört“

11. Prim.-sensori. Cortex Extro-ceptive & intro- ceptive Stimuli CSTC-Loop and Sensorimotor Gating Hippocampus -Glu RA +5-HT +5-HT +5-HT VTA +DA -DA Parietal cortex Temporal cortex C. m. Thalamus Frontal Cortex Striatum Pallidum

12. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S (2007) Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response - a double-blind PET study in schizophrenia. Neuropsychopharmacology 32: 1209-15 D2-Besetzung durch Neuroleptika und klinische Wirksamkeit I

13. D2-Besetzung durch Neuroleptika und klinische Wirksamkeit II

14. Fluoxetin (Prozac ® ) Klassischer SSRI (Selektiver Serotonin-Wiederaufnahme-Hemmer) „ Symbol of the 90ies“

15. Figure 2. Mean Standardized Improvement as a Function of Initial Severity and Treatment Group. Drug improvement is portrayed as red triangles around their solid red regression line and placebo improvement as blue circles around their dashed blue regression line; the green shaded area indicates the point at which comparisons of drug versus placebo reach the NICE clinical significance criterion of d ¼ 0.50. Plotted values are sized according to their weight in analyses. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, et al., PLoS Medicine Vol. 5, No. 2, e45 doi:10.1371/journal.pmed.0050045

16. Figure 3. Mean Standardized Improvement as a Function of Initial Severity and Treatment Group, Including Only Trials Whose Samples Had High Initial Severity Drug improvement is portrayed as red triangles around their solid red regression line and placebo improvement as blue circles around their dashed blue regression line; the green shaded area indicates the point at which comparisons of drug versus placebo reach the NICE clinical significance criterion of d ¼ 0.50. Plotted values are sized according to their weight in analyses. doi:10.1371/journal.pmed.0050045.g003

17. Neue Allianzen

18. „ Management of behaviour“